Janssen collaborates with Australian institute on Alzheimer's disease research

Australia’s St Vincent’s Institute of Medical Research (SVI) in Melbourne, has entered into a collaboration and license agreement with Janssen Pharmaceuticals, a subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ).

The partnership is aimed at developing and commercializing small molecule modulators of microglial function and inflammation, with the aim of reducing the amyloid plaque burden and Alzheimer’s disease severity. The collaboration was facilitated by Johnson & Johnson Innovation.

The collaboration leverages SVI research capability and the expertise of Professor Michael Parker – one of Australia’s leading structural biologists – with Janssen’s drug discovery and development expertise.